# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13G**

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2

(Amendment No.)

# Arvinas, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

04335A105 (CUSIP Number)

October 1, 2018 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names	Names of Reporting Persons.				
		New Leaf Ventures III, L.P. ("NLV III")				
2.	Check (a) □		ppropriate Box if a Member of a Group (See Instructions) b) ⊠			
3.	SEC U	Jse Or	ıly			
4.	Source	of Fu	ands (See Instructions)			
	WC					
5.	Check	if Dis	sclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)			
6.	Citizei	nship (	or Place of Organization			
	Delaw	are				
		7.	Sole Voting Power			
			1,908,048 shares, except that (a) New Leaf Venture Associates III, L.P. ("NLV Associates III"), the sole general partner of NLV III, may be deemed to have sole power to vote such shares, (b) New Leaf Venture Management III, L.L.C. ("NLV Management			
			III"), the sole general partner of NLV Associates III and ultimate general partner of NLV III, may be deemed to have sole power to vote such shares, and (c) Liam Ratcliffe, a member of the Issuer's board of directors ("Ratcliffe"), Ronald M. Hunt ("Hunt") and			
Num	ber of		Vijay K. Lathi ("Lathi"), the managers of NLV Management III, may each be deemed to have shared power to vote such shares.			
	ares	8.	Shared Voting Power			
	ficially ied by		See response to row 7.			
E	ach	9.	Sole Dispositive Power			
	orting rson		1,908,048 shares, except that (a) NLV Associates III, the sole general partner of NLV III, may be deemed to have sole power to			
	7ith		dispose of such shares, (b) NLV Management III, the sole general partner of NLV Associates III and ultimate general partner of			
			NLV III, may be deemed to have sole power to dispose of such shares, and (c) Ratcliffe, a member of the Issuer's board of			
			directors, Hunt and Lathi, the managers of NLV Management III, may each be deemed to have shared power to dispose of such shares.			
		10.	Shared Dispositive Power			
	See response to row 9.					
11.	Aggr	egate	Amount Beneficially Owned by Each Reporting Person			
	1,908	3,048				
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)					
13.	Perce	ent of	Class Represented by Amount in Row (11)			
	5.9%	1				
14.	Type	of Re	porting Person (See Instructions)			
	PN					

Based on 32,158,748 shares of the Issuer's Common Stock outstanding following the completion of its initial public offering and as reported on the Issuer's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-227112) with the United States Securities and Exchange Commission on September 27, 2018.

1.	Names of Reporting Persons.					
	New L	New Leaf Venture Associates III, L.P.				
	Check (a) □		ppropriate Box if a Member of a Group (See Instructions) b) ⊠			
3.	SEC U	se Or	nly			
4.	Source	of Fu	ands (See Instructions)			
	AF					
5.		if Dis	sclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)			
6.		ıship (	or Place of Organization			
		- r				
	Delaw					
		7.	Sole Voting Power			
			1,908,048 shares, all of which are owned by NLV III, except that (a) NLV Associates III, the sole general partner of NLV III, may			
			be deemed to have sole power to vote such shares, (b) NLV Management III, the sole general partner of NLV Associates III and			
			ultimate general partner of NLV III, may be deemed to have sole power to vote such shares, and (c) Ratcliffe, a member of the			
Num	ber of		Issuer's board of directors, Hunt and Lathi, the managers of NLV Management III, may each be deemed to have shared power to vote such shares.			
-	ares	8.	Shared Voting Power			
	ficially					
	ed by ach	9.	See response to row 7.  Sole Dispositive Power			
	orting	٦.	Sole Dispositive I ower			
	rson		1,908,048 shares, all of which are owned by NLV III, except that (a) NLV Associates III, the sole general partner of NLV III, may			
l w	ith		be deemed to have sole power to dispose of such shares, (b) NLV Management III, the sole general partner of NLV Associates III and ultimate general partner of NLV III, may be deemed to have sole power to dispose of such shares, and (c) Ratcliffe, a member			
			of the Issuer's board of directors, Hunt and Lathi, the managers of NLV Management III, may each be deemed to have shared			
			power to dispose of such shares.			
		10.	Shared Dispositive Power			
			See response to Row 9.			
11.	Aggr	egate	Amount Beneficially Owned by Each Reporting Person			
12	1,908		e Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)			
12.	Cilec	K II UI	le Aggregate Amount in Row (11) Excludes Certain Shares (See instructions)			
13.	13. Percent of Class Represented by Amount in Row (11)					
	5.9%	1				
14.			porting Person (See Instructions)			
	PN					

1.	Names	of R	eporting Persons.			
	New L	New Leaf Venture Management III, L.L.C.				
2.	Check (a) □		ppropriate Box if a Member of a Group (See Instructions) b) ⊠			
3.	SEC U	Jse Or	nly			
4.	Source	of Fu	ands (See Instructions)			
	AF					
5.	Check	if Dis	sclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)			
6.	Citizei	nship	or Place of Organization			
	Delaw	oro				
	Delaw	7.	Sole Voting Power			
		, ,				
			1,908,048 shares, all of which are directly owned by NLV III, except that (a) NLV Associates III, the sole general partner of NLV			
			III, may be deemed to have sole power to vote of such shares, (b) NLV Management III, the sole general partner of NLV Associates III and ultimate general partner of NLV III, may be deemed to have sole power to vote all of the shares directly owned			
			by NLV III, and (c) Ratcliffe, a member of the Issuer's board of directors, Hunt and Lathi, the managers of NLV Management III,			
Num	ber of		may each be deemed to have shared power to vote all of such shares.			
	ares	8.	Shared Voting Power			
	ficially ied by		See response to row 7.			
	ach	9.	Sole Dispositive Power			
	orting					
	rson ⁄ith		1,908,048 shares, all of which are directly owned by NLV III, except that (a) NLV Associates III, the sole general partner of NLV			
•	71111		III, may be deemed to have sole power to dispose of such shares, (b) NLV Management III, the sole general partner of NLV Associates III and ultimate general partner of NLV III, may be deemed to have sole power to dispose of the shares directly owned			
			by NLV III, and (c) Ratcliffe, a member of the Issuer's board of directors, Hunt and Lathi, the managers of NLV Management III,			
			may each be deemed to have shared power to dispose of all of such shares.			
		10.	Shared Dispositive Power			
			See response to row 9.			
11.	Aggr	egate	Amount Beneficially Owned by Each Reporting Person			
	1,908	ያ በ// ያ				
12.			e Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)			
			55 5 ( ) (			
13.	3. Percent of Class Represented by Amount in Row (11)					
	5.9%	1				
14.			porting Person (See Instructions)			
	00					

1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	Nov. Loof D	ionl	narma Opportunities II I D ("Diopharma II")
_	New Leaf Biopharma Opportunities II, L.P. ("Biopharma II")		
2			PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a) [] (1	b) 🛭	
3	SEC USE O	NLY	T
4	CITIZENSH	IIP (	OR PLACE OF ORGANIZATION
	Delaware		
		5	SOLE VOTING POWER
NUMBER OF			375,000 shares, except that (a) New Leaf BPO Associates II, L.P. ("NLBA II"), the sole general partner of Biopharma II, may be deemed to have sole power to vote such shares, (b) New Leaf BPO Management II, L.L.C. ("NLB Management II"), the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares, and (c) each of Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Isaac Manke ("Manke"), the managers of NLB Management II, may each be deemed to have shared power to vote such shares.
	SHARES	6	SHARED VOTING POWER
	EFICIALLY		
OWNED BY			See response to row 5.
	EACH	7	SOLE DISPOSITIVE POWER
REPORTING			
]	PERSON		375,000 shares, except that (a) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to
	WITH		dispose of such shares, (b) NLB Management II, the sole general partner of NLBA II and ultimate general partner of
			Biopharma II, may be deemed to have sole power to dispose of such shares, and (c) each of Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Manke, the managers of NLB Management II, may each be deemed to have shared power to dispose of such shares.
		8	SHARED DISPOSITIVE POWER
	T		See response to row 7.
9	AGGREG	ATE	E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	375,000 sh		
10	CHECK II	FTF	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11	PERCENT	OF	F CLASS REPRESENTED BY AMOUNT IN ROW (9)
	1.2%1		
12		REI	PORTING PERSON (SEE INSTRUCTIONS)
	PN		

	1					
1		NAMES OF REPORTING PERSONS				
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	New Leaf BPO Associates II, L.P.					
2			APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
_	(a) $\Box$					
3	SEC USE	ON	LY			
4	CITIZENS	SHII	P OR PLACE OF ORGANIZATION			
	Delaware					
	Delawale	5	SOLE VOTING POWER			
		J	SOLE VOINGTOWER			
			375,000 shares, all of which are owned by Biopharma II, except that (a) NLBA II, the sole general partner of Biopharma II,			
			may be deemed to have sole power to vote such shares, (b) NLB Management II, the sole general partner of NLBA II and			
			ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares, and (c) each of Ratcliffe, a			
			member of the Issuer's board of directors, Hunt, Lathi, and Manke, the managers of NLB Management II, may each be deemed to have shared power to vote such shares.			
	MBER OF	6	SHARED VOTING POWER			
	SHARES IEFICIALLY		SIMILE VOINGTOWER			
	WNED BY		See response to row 5.			
	EACH	7	SOLE DISPOSITIVE POWER			
	PORTING					
ŀ	PERSON WITH		375,000 shares, all of which are owned by Biopharma II, except that (a) NLBA II, the sole general partner of Biopharma II,			
	VV 1 1 1 1		may be deemed to have sole power to dispose of such shares, (b) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares, and (c) each of			
			Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Manke, the managers of NLB Management II, may			
			each be deemed to have shared power to dispose of such shares.			
		8	SHARED DISPOSITIVE POWER			
			See response to row 7.			
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	375,000 sha	res				
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	1.20/1					
10	1.2%1	ED	ORTING PERSON (SEE INSTRUCTIONS)			
12	I I PE OF R	LLP(	OKTING PERSON (SEE INSTRUCTIONS)			
	PN					

	1					
1		NAMES OF REPORTING PERSONS  LD C. IDENTIFICATION NOS. OF A BOYE BEDSONS (ENTIFIES ONLY)				
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	New Leaf BPO Management II, L.L.C.					
2			APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) □					
3	SEC USE ONLY					
4	CITIZENS	SHII	P OR PLACE OF ORGANIZATION			
	Delaware					
		5	SOLE VOTING POWER			
			375,000 shares, all of which are owned by Biopharma II, except that (i) NLBA II, the sole general partner of Biopharma II,			
			may be deemed to have sole power to vote such shares, (b) NLB Management II, the sole general partner of NLBA II and			
			ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares, and (c) each of Ratcliffe, a			
			member of the Issuer's board of directors, Hunt, Lathi, and Manke, the managers of NLB Management II, may each be			
	MBER OF	_	deemed to have shared power to vote such shares.  SHARED VOTING POWER			
	SHARES	6	SHARED VOTING POWER			
	EFICIALLY VNED BY		See response to row 5.			
	EACH	7	SOLE DISPOSITIVE POWER			
RE	PORTING					
F	PERSON		375,000 shares, all of which are owned by Biopharma II, except that (a) NLBA II, the sole general partner of Biopharma II,			
	WITH		may be deemed to have sole power to dispose of such shares, (b) NLB Management II, the sole general partner of NLBA II			
			and ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares, and (c) each of			
			Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Manke, the managers of NLB Management II, may each be deemed to have shared power to dispose of such shares.			
		8	SHARED DISPOSITIVE POWER			
			See response to row 7.			
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	375,000 shares					
10						
	_					
11	PERCENT	OF (	CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	1.2%1					
12		EP(	ORTING PERSON (SEE INSTRUCTIONS)			
	00		00			

1			REPORTING PERSONS IFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Ronald M	. Hı	unt
2	CHECK T (a) □		APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) ) ⊠
3	SEC USE	ON	ILY
4			P OR PLACE OF ORGANIZATION
	United Sta		
		5	SOLE VOTING POWER
			See response to row 6
		6	See response to row 6. SHARED VOTING POWER
			STRICE VOTING TOWER
NUMBER OF SHARES BENEFICIALLY OWNED BY		7	2,283,048 shares, of which (a) 1,908,048 are owned directly by NLV III and (b) 375,000 are owned directly by Biopharma II, except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to vote such shares owned by Biopharma II, (ii) NLV Associates III, the sole general partner of NLV III, may be deemed to have sole power to vote such shares owned by NLV III, (iii) NLB Management III, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares owned by Biopharma II, (iv) NLV Management III, the sole general partner of NLV III, may be deemed to have sole power to vote such shares directly owned by NLV III, (v) Ratcliffe, a member of the Issuer's board of directors, Hunt, and Lathi, the managers of NLV Management III, may each be deemed to have shared power to vote such shares owned by NLV III, and (vi) Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Manke, the managers of NLB Management II, may each be deemed to have shared power to vote such shares owned by Biopharma II.  SOLE DISPOSITIVE POWER
RE	EACH PORTING	,	SOLE DISTOSTITY ETOWER
I	PERSON		See response to row 8.
	WITH	8	SHARED DISPOSITIVE POWER
			2,283,048 shares, of which (a) 1,908,048 are owned directly by NLV III and (b) 375,000 are owned directly by Biopharma II, except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to dispose of such shares owned by Biopharma II, (ii) NLV Associates III, the sole general partner of NLV III, may be deemed to have sole power to dispose of such shares owned by NLV III, (iii) NLB Management III, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares owned by Biopharma II, (iv) NLV Management III, the sole general partner of NLV Associates III and ultimate general partner of NLV III, may be deemed to have sole power to dispose of such shares directly owned by NLV III, (v) Ratcliffe, a member of the Issuer's board of directors, Hunt, and Lathi, the managers of NLV Management III, may each be deemed to have shared power to dispose of such shares owned by NLV III, and (vi) Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Manke, the managers of NLB Management II, may each be deemed to have shared power to dispose of such shares owned by Biopharma II.
9	AGGREGA	TE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	2,283,048 shares		
10	2,283,048 snares CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW (9)
	7.11%		
12	TYPE OF F	REP	ORTING PERSON (SEE INSTRUCTIONS)
	IN		

1	1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)		
	Vijay K. L		
2	CHECK T (a) □		APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  ☑
3	SEC USE	ON	LY
4	CITIZENS	THE	P OR PLACE OF ORGANIZATION
4			
	United Sta		
		5	SOLE VOTING POWER
			See response to row 6.
		6	SHARED VOTING POWER
			2,283,048 shares, of which (a) 1,908,048 are owned directly by NLV III and (b) 375,000 are owned directly by Biopharma II,
			except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to vote such shares owned by Biopharma II, (ii) NLV Associates III, the sole general partner of NLV III, may be deemed to have sole power to
			vote such shares owned by NLV III, (iii) NLB Management III, the sole general partner of NLBA II and ultimate general
			partner of Biopharma II, may be deemed to have sole power to vote such shares owned by Biopharma II, (iv) NLV
			Management III, the sole general partner of NLV Associates III and ultimate general partner of NLV III, may be deemed to
NU	MBER OF		have sole power to vote such shares directly owned by NLV III, (v) Ratcliffe, a member of the Issuer's board of directors, Hunt, and Lathi, the managers of NLV Management III, may each be deemed to have shared power to vote such shares owned
	SHARES		by NLV III, and (vi) Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Manke, the managers of NLB
	IEFICIALLY WNED BY		Management II, may each be deemed to have shared power to vote such shares owned by Biopharma II.
0	EACH	7	SOLE DISPOSITIVE POWER
	PERSON		See response to row 8.
,	WITH	8	SHARED DISPOSITIVE POWER
			2 202 040 shows of shigh (s) 1 000 040 our sound directly by NIXV III and (b) 275 000 our sound directly by Disabours II
			2,283,048 shares, of which (a) 1,908,048 are owned directly by NLV III and (b) 375,000 are owned directly by Biopharma II, except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to dispose of such shares
			owned by Biopharma II, (ii) NLV Associates III, the sole general partner of NLV III, may be deemed to have sole power to
			dispose of such shares owned by NLV III, (iii) NLB Management III, the sole general partner of NLBA II and ultimate general
			partner of Biopharma II, may be deemed to have sole power to dispose of such shares owned by Biopharma II, (iv) NLV
			Management III, the sole general partner of NLV Associates III and ultimate general partner of NLV III, may be deemed to have sole power to dispose of such shares directly owned by NLV III, (v) Ratcliffe, a member of the Issuer's board of
			directors, Hunt, and Lathi, the managers of NLV Management III, may each be deemed to have shared power to dispose of
			such shares owned by NLV III and (vi) Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Manke, the
			managers of NLB Management II, may each be deemed to have shared power to dispose of such shares owned by Biopharma
9	ACCRECA	TF	II. AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3	AGGILGALE ANIOUNT DENERICIALLY OWNED BY EACH REPORTING PERSON		
	2,283,048 s		
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW (9)
	7.11%		
12		REP	ORTING PERSON (SEE INSTRUCTIONS)
	IN		
	11.4		

1			REPORTING PERSONS IFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Liam T. R			
2			APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
	(a) 🗆	(b)		
3	SEC USE	SEC USE ONLY		
4	CITIZENS	SHII	P OR PLACE OF ORGANIZATION	
	United Sta	ites	citizen	
		5	SOLE VOTING POWER	
			See response to row 6.	
		6	SHARED VOTING POWER	
			2 202 040 days of 11 day 4 000 040 are and 11 and 12 NIXVIII and (1) 275 000 are and 11 and 14 Displayer III	
			2,283,048 shares, of which (a) 1,908,048 are owned directly by NLV III and (b) 375,000 are owned directly by Biopharma II, except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to vote such shares	
			owned by Biopharma II, (ii) NLV Associates III, the sole general partner of NLV III, may be deemed to have sole power to	
			vote such shares owned by NLV III, (iii) NLB Management III, the sole general partner of NLBA II and ultimate general	
			partner of Biopharma II, may be deemed to have sole power to vote such shares owned by Biopharma II, (iv) NLV	
			Management III, the sole general partner of NLV Associates III and ultimate general partner of NLV III, may be deemed to	
NU	MBER OF		have sole power to vote such shares directly owned by NLV III, (v) Ratcliffe, a member of the Issuer's board of directors,	
	SHARES		Hunt, and Lathi, the managers of NLV Management III, may each be deemed to have shared power to vote such shares owned by NLV III, and (iii) Posteliffo, a marriage of the Jacquer's board of directors. Hunt, Lathi, and Marke, the managers of NLP.	
BEN	IEFICIALLY		by NLV III, and (vi) Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Manke, the managers of NLB Management II, may each be deemed to have shared power to vote such shares owned by Biopharma II.	
O	WNED BY	7	SOLE DISPOSITIVE POWER	
DI	EACH EPORTING	'		
	PERSON		See response to row 8.	
	WITH	8	SHARED DISPOSITIVE POWER	
			2,283,048 shares, of which (a) 1,908,048 are owned directly by NLV III and (b) 375,000 are owned directly by Biopharma II,	
			except that (i) NLBA II, the sole general partner of Biopharma II, may be deemed to have sole power to dispose of such shares	
			owned by Biopharma II, (ii) NLV Associates III, the sole general partner of NLV III, may be deemed to have sole power to	
			dispose of such shares owned by NLV III, (iii) NLB Management III, the sole general partner of NLBA II and ultimate general	
			partner of Biopharma II, may be deemed to have sole power to dispose of such shares owned by Biopharma II, (iv) NLV	
			Management III, the sole general partner of NLV Associates III and ultimate general partner of NLV III, may be deemed to	
			have sole power to dispose of such shares directly owned by NLV III, (v) Ratcliffe, a member of the Issuer's board of	
			directors, Hunt, and Lathi, the managers of NLV Management III, may each be deemed to have shared power to dispose of such shares owned by NLV III, and (vi) Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi, and Manke, the	
			managers of NLB Management II, may each be deemed to have shared power to dispose of such shares owned by Biopharma	
			II.	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
10	2,283,048 s		s E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
10	CHECK IF	1111	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	7 110/			
10	7.11%	יתקו	ODTING DEDGON (SEE INSTRUCTIONS)	
12	I I PE UF F	CP(	ORTING PERSON (SEE INSTRUCTIONS)	
	IN			

1		IES OF REPORTING PERSONS				
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)					
	Isaac Man	ke				
2			APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) 🗆	(b)				
3	SEC USE	ON	LY			
4	CITIZENS	SHII	P OR PLACE OF ORGANIZATION			
	United Sta	tes	citizen			
	•	5	SOLE VOTING POWER			
		-	See response to row 6.			
		6	SHARED VOTING POWER			
			375,000 shares, all of which are owned by Biopharma II, except that (a) NLBA II, the sole general partner of Biopharma II,			
NU	MBER OF		may be deemed to have sole power to vote such shares, (b) NLB Management II, the sole general partner of NLBA II and			
	SHARES		ultimate general partner of Biopharma II, may be deemed to have sole power to vote such shares, and (c) each of Hunt, Lathi,			
	EFICIALLY		Ratcliffe, a member of the Issuer's board of directors, and Manke, the managers of NLB Management II, may each be deemed			
0	WNED BY EACH	7	to have shared power to vote such shares.  SOLE DISPOSITIVE POWER			
RE	PORTING	′	SOLE DISTOSTITVE TOWER			
I	PERSON		See response to row 8.			
	WITH	8	SHARED DISPOSITIVE POWER			
			375,000 shares, all of which are owned by Biopharma II, except that (a) NLBA II, the sole general partner of Biopharma II,			
			may be deemed to have sole power to dispose of such shares, (b) NLB Management II, the sole general partner of NLBA II and ultimate general partner of Biopharma II, may be deemed to have sole power to dispose of such shares, and (c) each of			
			Hunt, Lathi, Ratcliffe, a member of the Issuer's board of directors, and Manke, the managers of NLB Management II, may			
			each be deemed to have shared power to dispose of such shares.			
9	AGGREGA	TE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	275 000 64-	noc				
10	375,000 sha		E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
10	CILLOIT		ENGOLEGINE TIMOGNI IN NOW (b) ENGLOBED GENTIMOSIINED (GEE INGINOGRA)			
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	1.11%					
12	TYPE OF F	EP	ORTING PERSON (SEE INSTRUCTIONS)			
	INI					
	IN					

Item 1(a). Name of Issuer:

Arvinas, Inc. (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

5 Science Park 395 Winchester Ave. New Haven, Connecticut 06511

#### Item 2(a). Name of Persons Filing:

This joint statement on Schedule 13G is being filed by New Leaf Ventures III, L.P. ("NLV III"), New Leaf Venture Associates III, L.P. ("NLV Associates III"), New Leaf Venture Management III, L.L.C. ("NLV Management III" and together with NLV Associates III and NLV III, the "NLV Reporting Entities"), New Leaf Biopharma Opportunities II, L.P. ("Biopharma II"), New Leaf BPO Associates II, L.P. ("NLBA II") and New Leaf BPO Management II, L.L.C. ("NLB Management II" and together with Biopharma II and NLBA II, the "BPO Reporting Entities") and Ronald M. Hunt ("Hunt"), Vijay K. Lathi ("Lathi"), Liam T. Ratcliffe ("Ratcliffe"), and Isaac Manke ("Manke" and, together with Hunt, Lathi, and Ratcliffe, the "Managing Directors"). The NLV Reporting Entities, BPO Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".

NLV Associates III is the sole general partner of NLV III and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by NLV III. NLV Management III is the sole general partner of NLV Associates III and the ultimate general partner of NLV III and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by NLV III. NLBA II is the sole general partner of Biopharma II and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Biopharma II. NLB Management II is the sole general partner of NLBA II and ultimate general partner of Biopharma II and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Biopharma II. Each of Ratcliffe, a member of the Issuer's board of directors, Hunt and Lathi are the managers of NLV Management III and may each be deemed to have shared power to vote and shared power to dispose of shares of the Issuer directly owned by NLV III. Each of Ratcliffe, a member of the Issuer's board of directors, Hunt, Lathi and Manke are the managers of NLB Management II and may be deemed to have shared power to vote and shared power by Biopharma II.

#### Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of NLV III, NLV Associates III, NLV Management III, Biopharma II, NLBA II, NLB Management III, Hunt, Ratcliffe and Manke is New Leaf Venture Partners, Times Square Tower, 7 Times Square, Suite 3502, New York, NY 10036.

The address of the principal business office of Lathi is New Leaf Venture Partners, 1200 Park Place, Suite 300, San Mateo, CA 94043.

#### Item 2(c). Citizenship:

Each of NLV III, NLV Associates III, Biopharma II and NLBA II is a limited partnership organized under the laws of the State of Delaware.

Each of NLV Management III and NLB Management II is a limited liability company organized under the laws of the State of Delaware.

Each Manager is a citizen of the United States.

Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, \$0.001 par value per share ("Common Stock").

Item 2(e). CUSIP Number:

04335A105

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

Not applicable.

#### Item 4. Ownership.

(a) Amount beneficially owned:

See line 9 of cover sheets. NLV III is the record owner of 1,908,048 shares of Common Stock of the Issuer (the "NLV III Shares"). As the sole general partner of NLV III, NLV Associates III may be deemed to own beneficially the NLV III shares. As the sole general partner of NLV Associates III and ultimate general partner of NLV III, NLV Management III may be deemed to own beneficially the NLV III shares. As the individual managers of NLV Management III, each of Ratcliffe, Hunt and Lathi may be deemed to own beneficially the NLV III Shares. Biopharma II is the record owner of the 375,000 shares of Common Stock (the "Biopharma II Shares"). As the sole general partner of Biopharma II, NLBA II may be deemed to own beneficially the Biopharma II shares. As the individual managers of NLB Management II may be deemed to own beneficially the Biopharma II Shares. As the individual managers of NLB Management II, each of Ratcliffe, Hunt, Lathi and Manke also may be deemed to own beneficially the Biopharma II Shares.

(b) Percent of class:

See Line 11 of cover sheets. The percentages set forth on the cover sheet for each Reporting Person are calculated based on 32,158,748 shares of Common Stock reported by the Issuer to be outstanding as of following the completion of the Issuer's initial public offering and as reported in its Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-227112) with the United States Securities and Exchange Commission on September 27, 2018.

- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote: see line 5 of cover sheets.
  - (ii) Shared power to vote or to direct the vote: see line 6 of cover sheets.
  - (iii) Sole power to dispose or to direct the disposition of: see line 7 of cover sheets.
  - (iv) Shared power to dispose or to direct the disposition of: see line 8 of cover sheets.

Each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record and to the extent of their pecuniary interest therein, if any.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

## Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Under certain circumstances set forth in the limited partnership agreements of each of NLV III, NLV Associates III, Biopharma II and NLBA II, and the limited liability company agreements of each of NLV Management III and NLB Management II, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

Item 7. <u>Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.</u>

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. <u>Notice of Dissolution of Group</u>.

Not applicable.

Item 10. <u>Certification</u>.

Not applicable.

Material to be Filed as Exhibits.

Exhibit 1- Agreement Regarding Joint Filing of Schedule 13G.

CUSIP No. 04335A105

#### 13G

## **SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 10, 2018

NEW LEAF VENTURES III, L.P.

By: New Leaf Venture Associates III, L.P. By: New Leaf Venture Management III, L.L.C.

By: /s/ Craig L. Slutzkin
Chief Financial Officer

NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.

By: New Leaf BPO Associates II, L.P. By: New Leaf BPO Management II, L.L.C.

By: /s/ Craig L. Slutzkin
Chief Financial Officer

NEW LEAF VENTURE ASSOCIATES III, L.P.

By: New Leaf Venture Management III, L.L.C.

By: /s/ Craig L. Slutzkin
Chief Financial Officer

NEW LEAF BPO ASSOCIATES II, L.P.

By: New Leaf BPO Management II, L.L.C.

By: /s/ Craig L. Slutzkin
Chief Financial Officer

NEW LEAF VENTURE MANAGEMENT III, L.L.C.

By: /s/ Craig L. Slutzkin
Chief Financial Officer

By:	/s/ Craig L. Slutzkin
	Chief Financial Officer
ISA	AC MANKE
By:	*
LIA	M RATCLIFFE
By:	*
	Liam Ratcliffe
ROI	NALD M. HUNT
ъ	
By:	
	Ronald M. Hunt
3711	AY K. LATHI
VIJI	AY K. LAIHI
By:	*
Dy.	Vijay K. Lathi
	vijay K. Laun
/s/ C	craig L. Slutzkin
	aig L. Slutzkin
	ttorney-in-fact

NEW LEAF BPO MANAGEMENT II, L.L.C.

<sup>\*</sup> This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.

#### AGREEMENT REGARDING JOINT FILING OF SCHEDULE 13G

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Arvinas, Inc.

Date: October 10, 2018

#### NEW LEAF VENTURES III, L.P.

By: New Leaf Venture Associates III, L.P.
By: New Leaf Venture Management III, L.L.C.

By: /s/ Craig L. Slutzkin
Chief Financial Officer

### NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.

By: New Leaf BPO Associates II, L.P. By: New Leaf BPO Management II, L.L.C.

By: /s/ Craig L. Slutzkin
Chief Financial Officer

#### NEW LEAF VENTURE ASSOCIATES III, L.P.

By: New Leaf Venture Management III, L.L.C.

By: /s/ Craig L. Slutzkin
Chief Financial Officer

#### NEW LEAF BPO ASSOCIATES II, L.P.

By: New Leaf BPO Management II, L.L.C.

By: /s/ Craig L. Slutzkin
Chief Financial Officer

By: /s/ Craig L. Slutzkin
Chief Financial Officer
NEW LEAF BPO MANAGEMENT II, L.L.C.
By: /s/ Craig L. Slutzkin
Chief Financial Officer
ISAAC MANKE
By: *
LIAM RATCLIFFE
By: *
Liam Ratcliffe
RONALD M. HUNT
By: *
Ronald M. Hunt
VIJAY K. LATHI
By: *
Vijay K. Lathi
/s/ Craig L. Slutzkin
* Craig L. Slutzkin
As attorney-in-fact

NEW LEAF VENTURE MANAGEMENT III, L.L.C.

<sup>\*</sup> This Schedule 13G was executed by Craig L. Slutzkin on behalf of the individuals listed above pursuant to Powers of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.